{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:12:06Z","timestamp":1791216726557,"version":"4.1.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients affected by very early onset inflammatory bowel disease (VEO-IBD) are frequently refractory to standard treatments. Despite the lack of randomized clinical trials, vedolizumab emerged as an effective and safe alternative treatment in VEO-IBD resistant to TNF antagonists. Here, we present a case of VEO-IBD with ulcerative colitis (UC) phenotype developing renal injury after vedolizumab administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>An 11-year-old female patient with VEO-UC was referred to our clinic for fever, nausea, and fatigue. She was treated with vedolizumab for 1 year due to steroid-dependent disease and failure of multiple therapies, including anti-TNF agents. At admission, she was in steroid-free clinical and endoscopic remission, with leukocytosis, increased inflammatory markers, and a rise in serum creatinine. Urine samples revealed persistent leukocyturia over the past 8\u201310 months with the absence of lower urinary tract symptoms and negative serial urine culture. MRI showed swollen-looking kidneys with bilateral irregular Diffusion-Weighted Imaging (DWI) signal restriction. Kidney biopsy revealed the presence of acute tubular damage with a mixed interstitial inflammatory infiltrate consistent with drug-induced acute tubulointerstitial nephritis (TIN). After prompt start of systemic glucocorticoid therapy and temporary discontinuation of vedolizumab, normalization of renal function and urinalysis was observed. Vedolizumab was restarted after 2 months, pre-medicated with steroids. The follow-up renal biopsy performed after 6 months showed a regression of the histological pattern, with chronic signs characterized by mild tubular atrophy and interstitial fibrosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Vedolizumab-related acute TIN is a potentially severe complication, rarely described in adult patients. We report the first case of VEO-IBD with a probable vedolizumab-related acute TIN treated with corticosteroids, with a good response and maintenance of vedolizumab. Persisting sterile leukocyturia could represent an early sign.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1684476","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:37:40Z","timestamp":1763534260000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Severe kidney involvement in a case of very early onset inflammatory bowel disease"],"prefix":"10.3389","volume":"16","author":[{"given":"Enrico","family":"Drago","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Carfora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Cafferata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Gaggero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Puzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"La Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Signa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gandullia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio Gaetano","family":"Vellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Angeletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Arrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.21349","article-title":"Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends","volume":"17","author":"Benchimol","year":"2011","journal-title":"Inflammation Bowel Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy068","article-title":"Diagnostic Yield of Next-generation Sequencing in Very Early-onset Inflammatory Bowel Diseases: A Multicentre Study [published correction appears in J Crohns Colitis. 2021 Mar 5;15(3):517-518","volume":"12","author":"Charbit-Henrion","year":"2018","journal-title":"J Crohns Colitis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac045","article-title":"Clinical phenotypes and outcomes in monogenic versus non-monogenic very early onset inflammatory bowel disease","volume":"16","author":"Collen","year":"2022","journal-title":"J Crohns Colitis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz259","article-title":"Very early onset inflammatory bowel disease: A clinical approach with a focus on the role of genetics and underlying immune deficiencies","volume":"26","author":"Ouahed","year":"2020","journal-title":"Inflammation Bowel Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz214","article-title":"The unique disease course of children with very early onset-inflammatory bowel disease","volume":"26","author":"Kelsen","year":"2020","journal-title":"Inflammation Bowel Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003464","article-title":"Utilization of antitumor necrosis factor biologics in very early onset inflammatory bowel disease: A multicenter retrospective cohort study from North America","volume":"75","author":"Kerur","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41385-021-00445-z","article-title":"Antibody secreting cells are critically dependent on integrin \u03b14\u03b27\/MAdCAM-1 for intestinal recruitment and control of the microbiota during chronic colitis","volume":"15","author":"Tyler","year":"2022","journal-title":"Mucosal Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/gutjnl-2018-316777","article-title":"Mechanism of action of vedolizumab: do we really understand it","volume":"68","author":"Rogler","year":"2019","journal-title":"Gut"},{"key":"B9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.5863\/1551-6776-26.8.795","article-title":"Vedolizumab: an emerging treatment option for pediatric inflammatory bowel disease","volume":"26","author":"Shah","year":"2021","journal-title":"J Pediatr Pharmacol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-021-04063-6","article-title":"Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study [published correction appears in Eur J Pediatr. 2021 May 23","volume":"180","author":"Garcia-Romero","year":"2021","journal-title":"Eur J Pediatr"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2017.08.008","article-title":"Interstitial nephritis secondary to vedolizumab treatment in crohn disease and safe rechallenge using steroids: A case report","volume":"71","author":"Bailly","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S2468-1253(22)00307-7","article-title":"Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study","volume":"8","author":"Atia","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.3390\/jcm10132997","article-title":"Safety and effectiveness of vedolizumab for the treatment of pediatric patients with very early onset inflammatory bowel diseases","volume":"10","author":"Fabiszewska","year":"2021","journal-title":"J Clin Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12887-022-03229-x","article-title":"Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review","volume":"22","author":"Fang","year":"2022","journal-title":"BMC Pediatr"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2024.2345383","article-title":"Acute interstitial nephritis in patients with inflammatory bowel disease treated with vedolizumab: a systematic review","volume":"59","author":"Forss","year":"2024","journal-title":"Scand J Gastroenterol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e00788","DOI":"10.14309\/crj.0000000000000788","article-title":"Vedolizumab-induced acute interstitial nephritis in ulcerative colitis","volume":"9","author":"Subhaharan","year":"2022","journal-title":"ACG Case Rep J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/01913123.2020.1839152","article-title":"Electron microscopic findings can support multiple etiologies of nephrotoxicity in renal tubules","volume":"44","author":"Zhang","year":"2020","journal-title":"Ultrastruct Pathol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e243568","DOI":"10.1136\/bcr-2021-243568","article-title":"Acute interstitial nephritis secondary to vedolizumab","volume":"14","author":"Simpson","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B19","article-title":"Acute interstitial nephritis with inflammatory bowel disease","volume":"27","author":"Jahan","year":"2022","journal-title":"Nephrology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.14309\/01.ajg.0000798812.13521.04","article-title":"P053\u2003Interstitial nephritis from IBD: complicated conclusions","volume":"116","author":"Kepley","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1681\/ASN.20203110S1688c","article-title":"Vedolizumab-induced acute interstitial nephritis and acute tubular necrosis: PO2260","volume":"31","author":"Muzib","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e254715","DOI":"10.1136\/bcr-2023-254715","article-title":"Vedolizumab-induced acute interstitial nephritis with failure of steroid prophylaxis on vedolizumab rechallenge","volume":"16","author":"O\u2019Leary","year":"2023","journal-title":"BMJ Case Rep"},{"key":"B23","first-page":"3","article-title":"Drug-induced acute interstitial nephritis: pathology, pathogenesis, and treatment","volume":"9","author":"Krishnan","year":"2015","journal-title":"Iran J Kidney Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2016.1181171","article-title":"Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis","volume":"12","author":"McLean","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2013010012","article-title":"Integrins in kidney disease","volume":"24","author":"Pozzi","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B26","article-title":"Acute interstitial nephritis in adolescents and young adults","volume":"10","author":"Greising","year":"1990","journal-title":"Child Nephrol Urol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2010.71","article-title":"Drug-induced acute interstitial nephritis","volume":"6","author":"Perazella","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12882-021-02358-2","article-title":"Different renal manifestations associated with very early onset pediatric inflammatory bowel disease: case report and review of literature","volume":"22","author":"Angeletti","year":"2021","journal-title":"BMC Nephrol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s40001-022-00687-y","article-title":"5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review","volume":"27","author":"Moss","year":"2022","journal-title":"Eur J Med Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1684476\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T06:37:46Z","timestamp":1763534266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1684476\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2025.1684476"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1684476","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"article-number":"1684476"}}